Not found, error 404
The page you are looking for no longer exists. Perhaps you can return back to the site's homepage and see if you can find what you are looking for. Or, you can try finding it by using the search form below.
Pages:
- #733 (no title)
- An Emergent Technologies Portfolio Company, Pure MHC, Participates in Melanoma Study That Captures International Media Attention.
- Blog
- Contact Us
- Current News
- Home
- How We Do It
- What We Do
- Who We Are
- Why And How We Do It
Categories:
Authors:
- Blake Harlan (1)
- Dr. Thomas Folks (1)
- Gina Lento, Ph.D. (2)
- Kris Looney (2)
- Thomas Harlan (41)
Monthly:
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- May 2013
- April 2013
Recent Posts:
- Big Data And The Acceleration Of New Medical Technologies
- Building On Past Successes: When It Makes Sense To Look Backward
- Why Our Partner Solutions Program Works
- What Happens When An Idea Has Too Many Potential Markets?
- Creating “A Company Of Giants.” Why It’s So Hard.
- Our Entrepreneur Venture Program: How It Connects Good Ideas With Passionate People
- Now That Ebola Has Had Its 15 Minutes, Let’s Look At Diseases That We Should Be More Afraid Of
- Mind The Gap: Managing Today’s Multi-Generational Work Environment.
- Leadership In The 21st Century: What Good Leadership Looks Like Today
- Unfamiliar Opportunity: Pitching An Angel Investor Who Doesn’t Know Your Business
- Weak Patents And Squatting: The Costs Of Ineffective IP Strategy
- World AIDS Day 2014: Progress And Challenges Of Changing Patient Demographics
- Co-Inventors: Common Ground To Higher Goals.
- Lung Cancer Awareness: Progress Against A Major Killer
- Immunizations: Pros Vs. Cons
- Protecting Intellectual Property: Do You Know Where The Threats Are?
- Overcoming Inertia: How Pharma Is Embracing Open Innovation
- This Month’s ASHI Meeting, And A New Milestone For A Top Pure Transplant Solutions Researcher
- Press Release: Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets
- Ebola Update: The Double-Edged Sword of Knowledge in Our Global Community
- The Impact of ACA And FDASIA On Rare Disease Drug Development: New Opportunities For Innovation
- HIV Dormant Strains And Cancer: How Genetic Modification Created A Powerful Potential Cancer Treatment
- Early Research Days of AIDs: Fighting an unknown killer
- Childhood Cancer Awareness Month: The Progress Down A Long Road
- Imagine a World Where Your Body Can Heal Itself – Of Almost Anything
- Why Do Drugs for Rare Disease Cost So Much?
- Controversy Rages Over Consumer Access to Genome Profiles
- Should We Bring Ebola Patients to the US for Treatment?
- Selenium Offers New Approach to Anti-Infective Product Development
- Could Cleaning CO2 from the Air Cause More Harm Than Good?
- Austin Nonprofit Brings Comprehensive Change to African Villages
- Biosurface Labeling – Provides Security & Virtually Eliminates Potential Error
- Scientific Community Decries Research Using Reverse Genetics
- Exposing the Shadowy World of Counterfeit Pharmaceuticals
- Novel Targeting Techniques to Treat Breast, Ovarian and Other Drug Resistant Cancers Set to Start Phase I Clinical Trials in 2015
- Bioethics of Innovations in Synthetic Biology
- Oklahoma Innovations – Biotech Finds a Home in OK
- The Pillars of Innovation
- Pushing Pedals for a Cure – An Emergent Tradition
- Team Emergent Helps Kids Build Brighter Futures
- Caisson Biotech Receives 2014 Buzz of BIO Nomination
- Biotech Breakthroughs – Changing the World One Innovation at a Time
- Skills That Great Leaders Need
- Perseverance, Attitude, and the Innovative Mindset
- The ABCs (and D) of Selecting the Right Partner
- Team Emergent Rides the MS 150 and raises over $15,000 to help fund Multiple Sclerosis research
- Welcome from the Founder